SOLV Energy (NASDAQ:MWH) announced its financial results for the fourth quarter and full fiscal year ended December 31, 2025, marking its first earnings report as a public company following its successful Nasdaq debut in February 2026.
Aveanna Healthcare Holdings (NASDAQ:AVAH) announced its financial results for the fourth quarter and full fiscal year ended December 31, 2025, reporting a period of accelerated growth and significant margin expansion.
Satellogic (NASDAQ:SATL), a leader in sub-meter resolution Earth Observation (EO) data, reported strong financial results for the fourth quarter and full year ended December 31, 2025.
Movado Group (NYSE:MOV) today announced its financial results for the fourth quarter and full fiscal year ended January 31, 2026, highlighting a period of robust operational leverage and steady top-line growth.
Titan Machinery (NASDAQ:TITN), a leading network of full-service agricultural and construction equipment dealerships, reported its financial results for the fourth quarter and full fiscal year ended January 31, 2026.
Lands’ End (NASDAQ:LE) reported financial results for the fourth quarter and full fiscal year ended January 30, 2026, headlined by a massive strategic pivot.
Solo Brands (NYSE:SBDS) reported its fourth-quarter and full-year 2025 financial results, marking a definitive chapter in its multi-year strategic restructuring.
Arcos Dorados Holdings (NYSE:ARCO), the world’s largest independent McDonald’s franchisee, reported record-breaking financial results for the fourth quarter and full year ended December 31, 2025.
Intuitive Machines (NASDAQ:LUNR) reported its fourth-quarter and full-year 2025 financial results on March 19, 2026, marking a pivotal shift from a specialized lunar lander developer to a diversified space infrastructure powerhouse.
Destination XL Group (NASDAQ:DXLG), the largest omni-channel specialty retailer of big and tall men’s apparel, announced its financial results for the fourth quarter and full fiscal year ended January 31, 2026.
Yiren Digital (NYSE:YRD) announced its unaudited financial results for the fourth quarter and full fiscal year ended December 31, 2025, revealing a significant shift in operational strategy toward capital preservation and risk mitigation.
Eli Lilly and Company (NYSE:LLY) today announced positive topline results from TRANSCEND-T2D-1, the first Phase 3 clinical trial evaluating retatrutide for the treatment of type 2 diabetes.
